Meanwhile, beta-blockers, mineralocorticoid receptor antagonists (MRA), inhibitors of the renin–angiotensin–aldosterone system, calcium-channel blockers and sodium-glucose cotransporter-2 (SGLT2) inhibitors were equally prescribed in AHF group and control group, given the fact that they are also indicated in chronic heart failure. The gene discussed is REN; the disease is congestive heart failure.